Novartis announced that Sandoz signed an MOU to build a new biologics production facility in Lendava, Slovenia. The investment is expected to be worth at least USD$400M and is one of the largest international private sector investments in Slovenia. Work on the new plant is set to begin in 2023, with full operations provisionally planned for late 2026.
This comes only a few weeks after Roche’s Genentech announced it is investing US$280M to build a new biologics manufacturing facility in Oceanside California that will begin operations in 2025.
–
Print Page Mail Article